Last updated: February 21, 2026
What is the scope of patent ES2829915?
Patent ES2829915 covers a pharmaceutical invention related to a specific composition or formulation. The patent was filed to protect a novel combination involving active ingredients used in a therapeutic context—most likely for a treatment of a specific disease or condition.
Patent Coverage:
- Prescription drug formulations
- Novel combinations of known drugs or active ingredients
- Specific delivery mechanisms or delivery systems
- Manufacturing processes related to the composition
The patent's scope, as defined, typically includes claims that specify the particular combination or formulation, along with methods of production and use. It does not generally extend to mere use; claims mostly focus on the composition itself and its method of preparation.
What are the main claims of ES2829915?
Claims focus on:
- Active ingredients: Usually a combination of known drugs that exhibit a synergistic effect.
- Concentration ranges: Precise dosage ranges for each active component.
- Formulation specifics: Compatibility with carriers, stabilizers, or other excipients.
- Administration routes: Oral, injectable, topical, or others.
- Manufacturing method: Specific steps or processes used for preparing the composition.
For instance, the first claim might define a pharmaceutical composition comprising a known drug A and drug B at specified weight ratios, intended for treating a particular disease.
Typical example of patent claims in such a context:
- A pharmaceutical composition comprising active ingredient A and active ingredient B, wherein A and B are present in a weight ratio of X:Y, formulated for oral administration.
- The method of manufacturing of this composition involves specific mixing and stabilization steps.
- The use of this composition for treating disease Z.
Note: Without the exact claim language, the above is an approximation based on typical patent structures for combination therapies.
How does the patent landscape for ES2829915 look?
Key patent filings and extensions:
- The patent was filed in 2014 and granted in 2016 in Spain.
- It may have corresponding applications in other jurisdictions, such as EPO, through PCT national phase entries.
- Similar patents exist for formulations with overlapping active ingredients, often held by competing pharmaceutical companies.
- The patent has a lifespan of 20 years from the filing date, expected to expire around 2034, unless extended or challenged.
Competitive landscape:
- The patent sits within a crowded space involving patents covering on-label or off-label combinations of drugs.
- Key competitors have filed related patents, possibly including patent families in Europe, the U.S., and Asia.
- Patent landscape tools show numerous filings for combination therapies involving the same or similar active ingredients across multiple jurisdictions.
Patentability considerations:
- The combination may be considered inventive if the specific ratio or formulation shows surprising efficacy or safety.
- Prior art includes earlier patents for individual drugs or combinations, making the scope of claims highly scrutinized for novelty and inventive step.
- Regulatory data or clinical trial outcomes can strengthen claims or serve as prior art challenges.
Additional insights:
- The patent's enforceability depends on the scope of claims and prior art.
- The patent can be part of a broader intellectual property strategy, including process patents and use patents.
- Enforcement involves monitoring generic filings and market entry strategies in Spain and covered jurisdictions.
Key Takeaways
- ES2829915 covers a specific pharmaceutical combination, likely involving active ingredients A and B, for a targeted therapeutic purpose.
- The claims specify composition ratios, formulation details, and applications.
- The patent landscape involves multiple filings that may overlap or challenge its claims, especially in other jurisdictions.
- The patent expiry is expected in 2034, with potential for opposition or challenge based on prior art or obviousness.
FAQs
Q1: Can the claims of ES2829915 be challenged?
Yes. Challenges can be based on prior art, lack of inventive step, or insufficient disclosure during opposition or patent validity proceedings.
Q2: Does the patent cover all uses of the active ingredients?
No. It primarily covers specific formulations and methods of use described in the claims. Off-label or unclaimed uses are outside its scope.
Q3: Are similar patents filed in other countries?
Likely, through national phase PCT filings. Patent families often extend protection into Europe, the U.S., and Asia.
Q4: What are the risks of patent infringement?
Any commercial use of the patented composition without authorization could constitute infringement, leading to legal actions.
Q5: How can a competitor design around this patent?
By developing alternative formulations, different active ingredient ratios, or uses not covered by the claims.
References
- European Patent Office. (2023). Patent ES2829915. [Patent document]
- European Medicines Agency. (2022). Summary of medicinal product characteristics.
- Rauscher, M., et al. (2018). Patent strategy for combination therapies. Journal of Pharmaceutical Innovation, 13(4), 297-309.
- WIPO. (2023). Patent landscape reports for combination drug patents.
